Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins-Reference-Cited by-同舟云学术

Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins

Published:2011-12-22 Issue:12 Volume:2 Page:1176-1190
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Vainio Paula¹,Lehtinen Laura¹,Mirtti Tuomas²³⁴,Hilvo Mika⁵,Seppänen-Laakso Tuulikki⁵,Virtanen Johannes¹,Sankila Anna⁴,Nordling Stig⁴,Lundin Johan³,Rannikko Antti⁶,Orešič Matej⁵,Kallioniemi Olli¹³,Iljin Kristiina¹

Affiliation:

1. Medical Biotechnology, VTT Technical Research Centre of Finland, and Turku Centre for Biotechnology, University of Turku, Finland

2. Haartman Institute, Department of Pathology, University of Helsinki, Finland

3. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Finland

4. HUSLAB, Department of Pathology, Helsinki University Central Hospital, Finland

5. Bio and Process Technology, VTT Technical Research Centre of Finland, Espoo, Finland

6. Department of Urology, Helsinki University Central Hospital, Finland

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. La phospholipase A2 associée aux lipoprotéines (Lp-PLA2) : biomarqueur pertinent et cible thérapeutique ?;Annales Pharmaceutiques Françaises;2024-09

2. Phospholipase A2 expression in prostate cancer as a biomarker of good prognosis: A comprehensive study in patients with long follow-up;Urologia Journal;2024-07-25

3. Phospholipase PLA2G7 is complementary to GPX4 in mitigating punicic-acid-induced ferroptosis in prostate cancer cells;iScience;2024-05

4. Co-inhibition of TGF-β and PD-L1 pathways in a metastatic colorectal cancer mouse model triggers interferon responses, innate cells and T cells, alongside metabolic changes and tumor resistance;OncoImmunology;2024-03-20

5. Proteomic profiling of IDH-wildtype Glioblastoma Tissue and Serum uncovers prognostic Subtypes and Marker Candidates;2024-03-04